Morrissey, K. M., Marchand, M., Patel, H., Zhang, R., Wu, B., Phyllis Chan, H., . . . Bruno, R. (2019). Alternative dosing regimens for atezolizumab: An example of model-informed drug development in the postmarketing setting. Cancer chemotherapy and pharmacology, 84(6), 1257-1267. https://doi.org/10.1007/s00280-019-03954-8
Citace podle Chicago (17th ed.)Morrissey, Kari M., et al. "Alternative Dosing Regimens for Atezolizumab: An Example of Model-informed Drug Development in the Postmarketing Setting." Cancer Chemotherapy and Pharmacology 84, no. 6 (2019): 1257-1267. https://doi.org/10.1007/s00280-019-03954-8.
Citace podle MLA (9th ed.)Morrissey, Kari M., et al. "Alternative Dosing Regimens for Atezolizumab: An Example of Model-informed Drug Development in the Postmarketing Setting." Cancer Chemotherapy and Pharmacology, vol. 84, no. 6, 2019, pp. 1257-1267, https://doi.org/10.1007/s00280-019-03954-8.